<unk>  is indicated for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. The medication has been found to significantly improve latency to persistent sleep (LPS), wake after sleep onset (WASO), and subjective total sleep time (TST) in regulatory clinical trials. At doses of 25 to 50mg and in terms of treatment–placebo difference, it reduces LPS by 6 to 12minutes, reduces WASO by 10 to 23minutes, and increases subjective TST by 10 to 22minutes.<unk>  has also been found to improve daytime functioning at a dose of 50mg but not at 25mg. It is the first insomnia medication to have been evaluated and shown effectiveness in improving not only nighttime symptoms but also daytime functioning. Network meta-analyses have found orexin receptor antagonists like suvorexant and lemborexant to be superior in sleep-promoting efficacy to many other sleep aids, such as benzodiazepines, Z-drugs, sedative antihistamines, sedative antidepressants (e.g., trazodone, mirtazapine, amitriptyline), and melatonin receptor agonists. However, comparative meta-analyses have not yet included<unk> , and hence it is unknown how this medication compares to other sleep aids. A 2022 network meta-analysis found similar efficacy between different orexin receptor antagonists including<unk> , although lemborexant may be more effective. Orexin receptor antagonists are not used as first-line treatments for insomnia due to their costs and concerns about possible misuse liability. Available forms<unk>  is available in the form of 25 and 50mg oral tablets. It is provided as the salt<unk>  hydrochloride, with each tablet containing 27 or 54mg of this substance (equivalent to 25 or 50mg<unk> .
Daridorexant
Seltorexant
Suvorexant
Veristrat
Bocasan
Toremifene
Icatibant
Fenproporex